Supplementary Information

Direct C–H alkylation and indole formation of anilines with diazo compounds under rhodium catalysis

Neeraj Kumar Mishra, Miji Choi, Hyeim Jo, Yongguk Oh, Satyasheel Sharma, Sang Hoon Han, Taejoo Jeong, Sangil Han, Seok-Yong Lee and In Su Kim*

School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea

* Corresponding author. Tel.: +82-31-290-7788; fax: +82-31-292-8800; e-mail: insukim@skku.edu

List of the Contents

General methods	S2
General procedure for the synthesis of pyrimidyl arylamines	\$3
General procedure for the synthesis of pyridinyl arylamines	S3
General procedure for the synthesis of diazo substrates	S3
Typical procedure for the alkylation of <i>N</i> -phenylpyrimidin-2-amines (3a–3u)	S4
Characterization data for alkylated products (3a–3u)	S5–S13
Typical procedure for the synthesis of indoles (5a-5p)	S14
Characterization data for indole products (5a-5p)	S15–S22
Experimental procedure and characterization for C7-alkylation of indole 5b	S23
Experimental procedure and characterization for C7-cyanation of indole 5b	S24
Experimental procedure and characterization for C7-amidation of indole 5b	S25
General procedure and characterization for the transformation of 3a	S26
Experimental procedure and characterization for deprotection of 5b	S27
Experimental procedure and characterization for the synthesis of deuterio-4a	S28
Kinetic isotope effect experiments	S29
¹ H NMR and ¹³ C NMR copies of all products	S30–S69

General methods

Commercially available reagents were used without additional purification, unless otherwise stated. Sealed tubes $(13 \times 100 \text{ mm}^2)$ were purchased from Fischer Scientific and dried in oven for overnight and cooled under a stream of nitrogen prior to use. Thin layer chromatography was carried out using plates coated with Kieselgel $60F_{254}$ (Merck). For flash column chromatography, E. Merck Kieselgel 60 (230-400 mesh) was used. Nuclear magnetic resonance spectra (¹H and ¹³C NMR) were recorded on a Bruker Unity 500 MHz and 700 MHz spectrometer for CDCl₃ solutions and chemical shifts are reported as parts per million (ppm) relative to, respectively, residual CHCl₃ $\delta_{\rm H}$ (7.24 ppm) and CDCl₃ $\delta_{\rm C}$ (77.23 ppm) as internal standards. Resonance patterns are reported with the notations s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). In addition, the notation br is used to indicate a broad signal. Coupling constants (*J*) are reported in hertz (Hz). IR spectra were recorded on a Varian 2000 Infrared spectrophotometer and are reported as cm⁻¹. High-resolution mass spectra (HRMS) were recorded on a JEOL JMS-600 spectrometer.

General procedure for the synthesis of pyrimidyl arylamines:¹⁻³ To an oven-dried flask charged with aniline (977.8 mg, 10.5 mmol, 150 mol %), 2-chloropyrimidine (801.7 mg, 7.0 mmol, 100 mol %) and acetic acid (7 mL) in 1,4-dioxane (19 mL) was added. The reaction mixture was stirred at 110 °C for 24 h and monitored by TLC. Upon completion, the mixture was extracted with CH_2Cl_2 (3 × 20 mL) and washed with brine. The organic layer was dried over Mg_2SO_4 and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc) to give *N*-phenylpyrimidin-2-amine **1a** (990.6 mg) in 82% yield.

General procedure for the synthesis of pyridinyl arylamines:¹⁻³ To an oven-dried flask charged with aniline (1.4 g, 15 mmol, 100 mol %), 2-bromopyridine (2.4 g, 15 mmol, 100 mol %) wad added. The reaction mixture was stirred at 160 °C for 7 h and monitored by TLC. Upon completion, saturated NaHCO₃ was added and the mixture was extracted with EtOAc (3×15 mL). The combined organic phase was washed with brine and dried over Mg₂SO₄. The solid was filtered off and the filtrate was evaporated in vacuum. The crude product was purified by flash column chromatography (*n*-hexanes/EtOAc) to give *N*-phenylpyridin-2-amine **4a** (2.44 g) in 95% yield.

General procedure for the synthesis of diazo substrates: Diazo substrates were prepared according to the previous literature.⁴

References:

- [1] X. Huang, S. Xu, Q. Tan, M. Gao, M. Lia and B. Xu, Chem. Commun., 2014, 50, 1465.
- [2] L. Ackermann and A. V. Lygin, Org. Lett., 2012, 14, 764.
- [3] G. Qian, B. Liu, Q. Tan, S. Zhang and B. Xu, Eur. J. Org. Chem., 2014, 4837.
- [4] N. D. Koduri, H. Scott, B. Hileman, J. D. Cox, M. Coffin, L. Glicksberg and S. R. Hussaini, Org. Lett., 2012, 14, 440.

Typical procedure for the alkylation of *N*-phenylpyrimidin-2-amines (3a–3u)

To an oven-dried sealed tube charged with *N*-phenylpyrimidin-2-amine (**1a**) (34.2 mg, 0.2 mmol, 100 mol %), [RhCp*Cl₂]₂ (3.1 mg, 0.005 mmol, 2.5 mol %), and AgOAc (5 mg, 0.03 mmol, 15 mol %) in MeOH (1 mL) was added dimethyl 2-diazomalonate (**2a**) (37.9 mg, 0.24 mmol, 120 mol %) under air. The reaction mixture was allowed to stir at 60 °C for 24 h, and cooled to room temperature. The reaction mixture was diluted with EtOAc (3 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc: 3:1) to afford **3a** (37.2 mg) in 62% yield.

Characterization data for alkylated products (3a–3u)

Dimethyl 2-(2-(pyrimidin-2-ylamino)phenyl)malonate (3a)



¹H NMR (500 MHz, CDCl₃) δ 8.34 (d, *J* = 4.5 Hz, 2H), 7.99 (br s, 1H), 7.67 (d, *J* = 8.0 Hz, 1H), 7.39–7.35 (m, 2H), 7.18 (d, *J* = 7.6 Hz, 1H), 6.67 (t, *J* = 4.5 Hz, 1H), 4.79 (s, 1H), 3.64 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 169.1, 160.7, 158.1, 137.6, 130.9, 129.1, 127.7, 126.5, 125.4, 112.4, 55.4, 52.9, 29.6; IR (KBr) υ 3359, 2953, 2924, 1728, 1577, 1509, 1438, 1404, 1246, 1149, 1024, 799, 755 cm⁻¹; HRMS (EI) calcd for C₁₅H₁₅N₃O₄ [M]⁺ 301.1063, found 301.1058.





¹H NMR (700 MHz, CDCl₃) δ 8.34 (d, J = 4.9 Hz, 2H), 8.16 (br s, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.38–7.35 (m, 2H), 7.16 (d, J = 7.7 Hz, 1H), 6.65 (t, J = 4.9 Hz, 1H), 4.72 (s, 1H), 4.17–4.13 (m, 2H), 4.11–4.06 (m, 2H), 1.17 (t, J = 7.0 Hz, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 168.7, 160.6, 158.0, 137.7, 131.0, 128.9, 127.4, 125.9, 125.0, 112.3, 62.0, 56.0, 13.8; IR (KBr) υ 3350, 2981, 2927, 1724, 1577, 1513, 1439, 1402, 1300, 1245, 1148, 1029, 799, 754 cm⁻¹; HRMS (EI) calcd for C₁₇H₁₉N₃O₄ [M]⁺ 329.1376, found 329.1375.

Diisopropyl 2-(2-(pyrimidin-2-ylamino)phenyl)malonate (3c)



¹H NMR (700 MHz, CDCl₃) δ 8.34 (d, J = 4.9 Hz, 2H), 8.31 (br s, 1H), 7.77 (d, J = 7.7 Hz, 1H), 7.35–7.41 (m, 2H), 7.13 (d, J = 7.7 Hz, 1H), 6.64 (t, J = 4.5 Hz, 1H), 5.01–4.97 (m, 2H), 4.67 (s, 1H), 1.21 (d, J = 6.3 Hz, 6H), 1.13 (d, J = 6.3 Hz, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 168.3, 160.5, 158.0, 137.8, 131.1, 128.8, 127.1, 125.2, 124.6, 112.3, 69.8, 56.5, 21.4, 21.3; IR (KBr) ν 3351, 2980, 2925, 1722, 1578, 1516, 1442, 1405, 1239, 1159, 1097, 995, 905, 799, 754 cm⁻¹; HRMS (EI) calcd for C₁₉H₂₃N₃O₄ [M]⁺ 357.1689, found 357.1691.

Di-tert-butyl 2-(2-(pyrimidin-2-ylamino)phenyl)malonate (3d)



¹H NMR (500 MHz, CDCl₃) δ 8.43 (br s, 1H), 8.36 (d, *J* = 5.0 Hz, 2H), 7.72 (d, *J* = 8.0 Hz, 1H), 7.36–7.32 (m, 2H), 7.11 (d, *J* = 7.7 Hz, 1H), 6.41 (t, *J* = 5.0 Hz, 1H), 4.58 (s, 1H), 1.39 (s, 18H); ¹³C NMR (125 MHz, CDCl₃) δ 168.0, 160.6, 158.0, 137.8, 131.2, 128.5, 127.2, 124.9, 124.4, 112.2, 82.6, 58.3, 27.7; IR (KBr) υ 3342, 2978, 2930, 1712, 1578, 1519, 1441, 1367, 1247, 1131, 799, 754 cm⁻¹; HRMS (EI) calcd for C₂₁H₂₇N₃O₄ [M]⁺ 385.2002, found 385.2002.

Dibenzyl 2-(2-(pyrimidin-2-ylamino)phenyl)malonate (3e)



¹H NMR (700 MHz, CDCl₃) δ 8.28 (d, *J* = 4.9 Hz, 2H), 8.03 (br s, 1H), 7.69 (d, *J* = 8.4 Hz, 1H), 7.41–7.38 (m, 2H), 7.30–7.29 (m, 6H), 7.26–7.25 (m, 4H), 7.19 (d, *J* = 7.7 Hz, 1H), 6.63 (t, *J* = 4.9 Hz, 1H), 5.15 (d, *J* = 11.9 Hz, 2H), 5.04 (d, *J* = 12.6 Hz, 2H), 4.90 (s, 1H); ¹³C NMR (175 MHz, CDCl₃) δ 168.4, 160.6, 158.0, 137.6, 135.0, 130.9, 129.1, 128.4, 128.3, 128.2, 127.6, 126.1, 125.3, 112.4, 67.6, 55.4; IR (KBr) v 3358, 2957, 2924, 1725, 1577, 1440, 1218, 1136, 1002, 799, 748, 697 cm⁻¹; HRMS (EI) calcd for C₂₇H₂₃N₃O₄ [M]⁺ 453.1689, found 453.1683.



¹H NMR (500 MHz, CDCl₃) δ 8.39 (d, *J* = 4.5 Hz, 2H), 7.94 (br s, 1H), 7.72–7.71 (m, 3H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.45 (t, *J* = 7.5 Hz, 2H), 7.40 (t, *J* = 9.0 Hz, 1H), 7.29 (d, *J* = 8.0 Hz, 1H), 7.05 (t, *J* = 8.0 Hz, 1H), 6.74 (d, *J* = 4.5 Hz, 1H), 5.69 (s, 1H), 3.65 (s, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 165.3, 160.6, 158.1, 138.6, 135.8, 134.3, 130.3, 130.2, 130.1, 128.5, 126.1, 125.2, 121.9, 112.9, 69.9, 53.0; IR (KBr) υ 3354, 2954, 2923, 1743, 1577, 1513, 1440, 1405, 1322, 1309, 1144, 1080, 799, 758, 686 cm⁻¹; HRMS (EI) calcd for C₁₉H₁₇N₃O₄S [M]⁺ 383.0940, found 383.0949.

Ethyl 2-(diethoxyphosphoryl)-2-(2-(pyrimidin-2-ylamino)phenyl)acetate (3g)



¹H NMR (700 MHz, CDCl₃) δ 8.63 (br s, 1H), 8.38 (br s, 2H), 7.74 (d, *J* = 7.7 Hz, 1H), 7.61 (d, *J* = 7.7 Hz, 1H), 7.34 (t, *J* = 7.7 Hz, 1H), 7.16 (t, *J* = 7.7 Hz, 1H), 6.68 (t, *J* = 4.9 Hz, 1H), 4.57 (d, *J* = 2.8 Hz, 1H), 4.16–3.99 (m, 6H), 1.25 (t, *J* = 7.0 Hz, 3H), 1.21 (t, *J* = 7.0 Hz, 3H), 7.15 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 167.5, 160.3, 158.0, 137.5 (d, *J*_{C-P} = 5.6 Hz), 130.1 (d, *J*_{C-P} = 5.0 Hz), 128.5 (d, *J*_{C-P} = 2.8 Hz), 125.5, 125.0 (d, *J*_{C-P} = 2.1 Hz), 124.5 (d, *J*_{C-P} = 8.5 Hz), 112.2, 64.0 (d, *J*_{C-P} = 7.0 Hz), 63.3 (d, *J*_{C-P} = 7.0 Hz), 61.8, 48.1 (d, *J*_{C-P} = 137.3 Hz), 16.3 (d, *J*_{C-P} = 5.6 Hz), 16.2 (d, *J*_{C-P} = 5.9 Hz), 13.8; IR (KBr) υ 3262, 2981, 2926, 1730, 1577, 1517, 1439, 1405, 1237, 1016, 962, 797, 751 cm⁻¹; HRMS (EI) calcd for C₁₈H₂₄N₃O₅P [M]⁺ 393.1454, found 393.1452.

Diisopropyl 2-(2-(pyridin-2-ylamino)phenyl)malonate (3h)



¹H NMR (500 MHz, CDCl₃) δ 8.14 (d, *J* = 5.0 Hz, 1H), 7.60 (br s, 1H), 7.55 (d, *J* = 8.0 Hz, 1H), 7.41 (t, *J* = 8.0 Hz, 1H), 7.36–7.30 (m, 2H), 7.13 (d, *J* = 7.5 Hz, 1H), 6.65 (t, *J* = 5.0 Hz, 1H), 6.60 (d, *J* = 8.5 Hz, 1H), 4.98–4.93 (m, 2H), 4.70 (s, 1H), 1.19 (d, *J* = 6.0 Hz, 6H), 1.14 (d, *J* = 6.0 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 168.4, 156.5, 147.9, 139.3, 137.5, 131.5, 129.1, 128.4, 124.9, 124.6, 108.4, 56.2, 21.4; IR (KBr) υ 3362, 2981, 2931, 1715, 1592, 1441, 1299, 1220, 1161, 1097, 769 cm⁻¹; HRMS (EI) calcd for C₂₀H₂₄N₂O₄ [M]⁺ 356.1736, found 356.1737.

Diisopropyl 2-(5-methoxy-2-(pyrimidin-2-ylamino)phenyl)malonate (3i)



¹H NMR (500 MHz, CDCl₃) δ 8.32 (d, J = 4.5 Hz, 2H), 7.75 (br s, 1H), 7.51 (d, J = 9.0 Hz, 1H), 6.97 (d, J = 2.5 Hz, 1H), 6.91 (dd, J = 8.5, 2.5 Hz, 1H), 6.61 (t, J = 5.0 Hz, 1H), 5.01–4.96 (m, 2H), 4.67 (s, 1H), 3.80 (s, 3H), 1.22 (d, J = 6.0 Hz, 6H), 1.14 (d, J = 6.0 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 168.0, 161.1, 158.0, 156.9, 130.3, 129.7, 127.6, 116.0, 114.3, 111.9, 69.7, 55.8, 55.4, 21.5, 21.4; IR (KBr) ν 3364, 2980, 2930, 1724, 1582, 1505, 1445, 1231, 1160, 1096, 1039, 983, 903, 800 cm⁻¹; HRMS (EI) calcd for C₂₀H₂₅N₃O₅ [M]⁺ 387.1794, found 387.1797.

Diisopropyl 2-(5-methyl-2-(pyrimidin-2-ylamino)phenyl)malonate (3j)



¹H NMR (400 MHz, CDCl₃) δ 8.32 (d, J = 4.8 Hz, 2H), 8.07 (br s, 1H), 7.57 (d, J = 6.8 Hz, 1H), 7.16 (d, J = 6.4 Hz, 2H), 6.62 (t, J = 4.8 Hz, 1H), 5.02–4.96 (m, 2H), 4.64 (s, 1H), 2.33 (s, 3H), 1.21 (d, J = 6.4 Hz, 6H), 1.13 (d, J = 6.4 Hz, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 168.3, 160.8, 158.0, 134.9, 134.7, 131.6, 129.5, 127.5, 125.7, 112.0, 69.7, 56.2, 21.5,21.4, 20.8; IR (KBr) υ 3347, 2980, 2925, 1723, 1581, 1517, 1444, 1410, 1242, 1163, 1097, 987, 905, 800 cm⁻¹; HRMS (EI) calcd for C₂₀H₂₅N₃O₄ [M]⁺ 371.1845, found 371.1843.

Diisopropyl 2-(5-butyl-2-(pyrimidin-2-ylamino)phenyl)malonate (3k)



¹H NMR (500 MHz, CDCl₃) δ 8.32 (br s, 2H), 8.05 (br s, 1H), 7.60 (d, *J* = 8.5 Hz, 1H), 7.16 (d, *J* = 6.5 Hz, 2H), 6.61 (t, *J* = 8.5 Hz, 1H), 5.01–4.96 (m, 2H), 4.65 (s, 1H), 2.58 (t, *J* = 7.5 Hz, 2H), 1.61–1.56 (m, 2H), 1.38–1.34 (m, 2H), 1.22 (d, *J* = 6.5 Hz, 6H), 1.13 (d, *J* = 6.0 Hz, 6H), 0.91(t, *J* = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.3, 160.9, 158.0, 139.5, 135.2, 130.9, 128.8, 127.2, 125.4, 112.0, 69.6, 56.2, 35.0, 33.4, 22.3, 21.5, 21.4, 13.9; IR (KBr) υ 3349, 2980, 2930, 1725, 1581, 1518, 1446, 1164, 1099, 987, 907, 799 cm⁻¹; HRMS (EI) calcd for C₂₃H₃₁N₃O₄ [M]⁺ 413.2315, found 413.2315.

Diisopropyl 2-(5-chloro-2-(pyrimidin-2-ylamino)phenyl)malonate (31)



¹H NMR (500 MHz, CDCl₃) δ 8.34 (d, J = 4.5 Hz, 2H), 8.26 (br s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.34 (s, 1H), 7.30 (dd, J = 8.5, 2.5 Hz, 1H), 6.66 (t, J = 5.0 Hz, 1H), 5.02–4.97 (m, 2H), 4.61 (s, 1H), 1.21 (d, J = 6.5 Hz, 6H), 1.13 (d, J = 6.0 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 167.8, 160.4, 158.0, 136.6, 131.0, 129.4, 128.8, 128.4, 126.4, 112.7, 70.1, 56.2, 21.4, 21.3; IR (KBr) ν 3341, 2981, 2933, 1720, 1577, 1508, 1444, 1407, 1245, 1165, 1095, 976, 903, 798 cm⁻¹; HRMS (EI) calcd for C₁₉H₂₂ClN₃O₄ [M]⁺ 391.1299, found 391.1299.

Diisopropyl 2-(2-(pyrimidin-2-ylamino)-5-(trifluoromethyl)phenyl)malonate (3m)



¹H NMR (500 MHz, CDCl₃) δ 8.70 (s, 1H), 8.40 (d, *J* = 4.5 Hz, 2H), 8.08 (d, *J* = 8.5 Hz, 1H), 7.60–7.57 (m, 2H), 6.73 (t, *J* = 5.0 Hz, 1H), 5.04–5.00 (m, 2H), 4.68 (s, 1H), 1.22 (d, *J* = 6.0 Hz, 6H), 1.14 (d, *J* = 6.5 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 167.9, 160.0, 158.1, 141.5, 128.5 (q, *J*_{C-F} = 3.6 Hz), 126.0, 125.9 (q, *J*_{C-F} = 3.6 Hz), 125.4 (q, *J*_{C-F} = 32.6 Hz), 125.1, 124.2, 122.9, 113.3, 56.9, 21.4, 21.3; IR (KBr) υ 3353, 2984, 2936, 1722, 1578, 1525, 1447, 1423, 1330, 1303, 1163, 1101 cm⁻¹; HRMS (EI) calcd for C₂₀H₂₂F₃N₃O₄ [M]⁺ 425.1562, found 425.1565.

Diisopropyl 2-(5-(ethoxycarbonyl)-2-(pyrimidin-2-ylamino)phenyl)malonate (3n)



¹H NMR (500 MHz, CDCl₃) δ 8.87 (s, 1H), 8.40 (d, J = 5.0 Hz, 2H), 8.10 (d, J = 8.5 Hz, 1H), 7.96 (s, 1H), 6.70 (t, J = 5.0 Hz, 1H), 5.05–5.00 (m, 2H), 4.69 (s, 1H), 4.35 (q, J = 7.0 Hz, 2H), 1.37 (t, J = 7.5 Hz, 3H), 1.22 (d, J = 6.0 Hz, 6H), 1.12 (d, J = 6.0 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 168.2, 166.0, 160.0, 158.0, 142.7, 133.2, 130.3, 125.2, 125.0, 123.0, 113.2, 70.2, 60.8, 57.4, 21.4, 21.3, 14.3; IR (KBr) υ 3335, 2980, 2923, 1711, 1576, 1519, 1444, 1415, 1278, 1171, 1095, 1017, 988, 913, 797, 766 cm⁻¹; HRMS (EI) calcd for C₂₂H₂₇N₃O₆ [M]⁺ 429.1900, found 429.1902.

Diisopropyl 2-(4-methoxy-2-(pyrimidin-2-ylamino)phenyl)malonate (30)



¹H NMR (500 MHz, CDCl₃) δ 8.36–8.35 (m, 3H), 7.44 (d, *J* = 2.5 Hz, 1H), 7.24 (d, *J* = 8.5 Hz, 1H), 6.68–6.64 (m, 2H), 5.02–4.97 (m, 2H), 4.60 (s, 1H), 3.80 (s, 3H), 1.21 (d, *J* = 6.0 Hz, 6H), 1.14 (d, *J* = 6.0 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 168.6, 160.4, 159.8, 158.0, 138.8, 131.9, 118.9, 112.4, 110.5, 110.0, 69.7, 55.9, 55.2, 21.5, 21.4; IR (KBr) υ 3345, 2980, 2925, 1720, 1577, 1520, 1442, 1254, 1165, 1098, 800 cm⁻¹; HRMS (EI) calcd for C₂₀H₂₅N₃O₅ [M]⁺ 387.1794, found 387.1793.

Diisopropyl 2-(4-methyl-2-(pyrimidin-2-ylamino)phenyl)malonate (3p)



¹H NMR (400 MHz, CDCl₃) δ 8.36 (d, J = 4.8 Hz, 2H), 8.26 (br s, 1H), 7.57 (s, 1H), 7.28 (d, J = 2.8 Hz, 1H), 6.98 (d, J = 7.6 Hz, 1H), 6.66 (t, J = 4.8 Hz, 1H), 5.05–4.99 (m, 2H), 4.67 (s, 1H), 2.37 (s, 3H), 1.23 (d, J = 6.4 Hz, 6H), 1.15 (d, J = 6.0 Hz, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 168.4, 160.5, 157.9, 138.8, 137.3, 130.9, 125.9, 125.8, 124.4, 112.1, 69.6, 56.0, 21.5, 21.4, 21.3; IR (KBr) υ 3354, 2980, 2927, 1723, 1576, 1524, 1444, 1253, 1165, 1099, 801 cm⁻¹; HRMS (EI) calcd for C₂₀H₂₅N₃O₄ [M]⁺ 371.1845, found 371.1843.

Diisopropyl 2-(4-ethyl-2-(pyrimidin-2-ylamino)phenyl)malonate (3q)



¹H NMR (700 MHz, CDCl₃) δ 8.35 (d, J = 4.9 Hz, 2H), 8.23 (br s, 1H), 7.54 (s, 1H), 7.29 (d, J = 7.7 Hz, 1H), 7.00 (d, J = 7.7 Hz, 1H), 6.65 (t, J = 4.9 Hz, 1H), 5.02–4.98 (m, 2H), 4.65 (s, 1H), 2.68 (q, J = 7.7 Hz, 2H), 1.23–1.21 (m, 9H), 1.14 (d, J = 6.3 Hz, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 168.4, 160.4, 158.0, 145.0, 137.2, 130.9, 125.0, 124.8, 124.7, 112.1, 69.7, 55.8, 28.5, 21.5, 21.4, 15.0; IR (KBr) υ 3350, 2978, 2932, 1721, 1574, 1523, 1445,

1428, 1402, 1160, 1097, 800 cm⁻¹; HRMS (EI) calcd for $C_{21}H_{27}N_3O_4$ [M]⁺ 385.2002, found 385.1999.

Diisopropyl 2-(4-fluoro-2-(pyrimidin-2-ylamino)phenyl)malonate (3r)



¹H NMR (400 MHz, CDCl₃) δ 8.76 (s, 1H), 8.37 (d, J = 4.8 Hz, 2H), 7.70 (d, J = 8.0 Hz, 1H), 7.34–7.28 (m, 1H), 6.87 (t, J = 8.8 Hz, 1H), 6.68 (t, J = 4.8 Hz, 1H), 5.08 (s, 1H), 5.02–4.96 (m, 2H), 1.22 (d, J = 6.4 Hz, 6H), 1.11 (d, J = 6.4 Hz, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 168.2, 160.9 (d, $J_{C-F} = 243.9$ Hz), 160.0, 157.9, 138.8, 129.4 (d, $J_{C-F} = 10.1$ Hz), 120.2, 114.6, 112.7, 110.6 (d, $J_{C-F} = 22.9$ Hz), 70.2, 48.7, 21.4, 21.3.; IR (KBr) v 3337, 2982, 2926, 1721, 1575, 1517. 1438, 1401, 1235, 1171, 1098, 798 cm⁻¹; HRMS (EI) calcd for C₁₉H₂₂FN₃O₄ [M]⁺ 375.1594, found 375.1595.

Diisopropyl 2-(4-chloro-2-(pyrimidin-2-ylamino)phenyl)malonate (3s)



¹H NMR (400 MHz, CDCl₃) δ 8.46 (s, 1H), 8.37 (d, J = 4.8 Hz, 2H), 7.92 (d, J = 2.0 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.08 (dd, J = 8.0, 2.0 Hz, 1H), 6.70 (t, J = 4.8 Hz, 1H), 5.04–4.98 (m, 2H), 4.63 (s, 1H), 1.21 (d, J = 6.4 Hz, 6H), 1.13 (d, J = 6.4 Hz, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 168.0, 160.0, 158.0, 139.0, 134.3, 132.1, 124.7, 124.6, 124.3, 112.9, 70.0, 56.1, 21.4, 21.3; IR (KBr) υ 3272, 2980, 2924, 1576, 1519, 1446, 1417, 1240, 1098, 994, 935, 796, 772 cm⁻¹; HRMS (EI) calcd for C₁₉H₂₂ClN₃O₄ [M]⁺ 391.1299, found 391.1300.

Diisopropyl 2-(3-(pyrimidin-2-ylamino)naphthalen-2-yl)malonate (3t)



¹H NMR (500 MHz, CDCl₃) δ 8.30 (br s, 1H), 8.22 (br s, 2H), 8.02 (d, *J* = 8.0 Hz, 1H), 7.89–7.86 (m, 2H), 7.74 (d, *J* = 8.5 Hz, 1H), 7.50–7.44 (m, 2H), 6.58 (t, *J* = 5.0 Hz, 1H), 5.16 (s, 1H), 5.04–4.99 (m, 2H), 1.24 (d, *J* = 6.5 Hz, 6H), 1.15 (d, *J* = 6.5 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 167.8, 162.1, 158.3, 134.1, 133.1, 131.1, 129.4, 128.2, 127.4, 127.0, 126.5, 126.3, 123.6, 111.9, 69.3, 54.4, 21.6, 21.5; IR (KBr) v 3199, 2980, 2933, 1726, 1585, 1519, 1446, 1374, 1263, 1162, 1100, 995, 904, 801 cm⁻¹; HRMS (EI) calcd for C₂₃H₂₅N₃O₄ [M]⁺ 407.1845, found 407.1840.

Diisopropyl 2-(3-methyl-2-(pyrimidin-2-ylamino)phenyl)malonate (3u)



¹H NMR (400 MHz, CDCl₃) δ 8.31 (d, J = 4.8 Hz, 2H), 7.54 (br s, 1H), 7.32 (dd, J = 7.2, 1.6 Hz, 1H), 7.27–7.20 (m, 2H), 6.63 (t, J = 4.8 Hz, 1H), 4.97–4.90 (m, 2H), 4.77 (s, 1H), 2.23 (s, 3H), 1.21 (d, J = 6.4 Hz, 6H), 1.15 (d, J = 6.4 Hz, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 168.0, 160.7, 158.1, 136.9, 135.4, 131.5, 130.9, 128.1, 127.0, 111.6, 69.4, 55.2, 21.5, 18.9; IR (KBr) υ 3216, 2979, 2932, 1725, 1580, 1445, 1228, 1157, 1097, 994, 913, 800 cm⁻¹; HRMS (EI) calcd for C₂₀H₂₅N₃O₄ [M]⁺ 371.1845, found 371.1844.

Typical procedure for the synthesis of indoles (5a–5p)

To an oven-dried sealed tube charged with *N*-phenylpyridin-2-amine (**4a**) (34.0 mg, 0.2 mmol, 100 mol %), [RhCp*Cl₂]₂ (3.1 mg, 0.005 mmol, 2.5 mol %), and AgOAc (5 mg, 0.03 mmol, 15 mol %) in MeOH (1 mL) was added ethyl 2-diazo-3-oxobutanoate (**2h**) (37.5 mg, 0.24 mmol, 120 mol %) under air. The reaction mixture was allowed to stir at 60 °C for 24 h, and cooled to room temperature. The reaction mixture was diluted with EtOAc (3 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc: 5:1) to afford **5b** (52.8 mg) in 94% yield.

Characterization data for indole products (5a–5p)

Ethyl 2-methyl-1-(pyrimidin-2-yl)-1H-indole-3-carboxylate (5a)



¹H NMR (400 MHz, CDCl₃) δ 8.89 (d, J = 4.8 Hz, 2H), 8.17 (d, J = 8.0 Hz, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.32 (t, J = 4.8 Hz, 1H), 7.29–7.22 (m, 2H), 4.44 (q, J = 7.2 Hz, 2H), 2.95 (s, 3H), 1.48 (t, J = 7.2 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 165.9, 158.5, 157.3, 145.5, 135.9, 127.1, 123.2, 122.9, 121.3, 118.8, 112.4, 108.3, 59.8, 14.5, 14.3; IR (KBr) υ 2978, 2929, 1659, 1564, 1551, 1456, 1418, 1399, 1193, 1094, 1024, 748 cm⁻¹; HRMS (EI) calcd for C₁₆H₁₅N₃O₂ [M]⁺ 281.1164, found 281.1167.

Ethyl 2-methyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (5b)



¹H NMR (700 MHz, CDCl₃) δ 8.81 (br s, 1H), 8.28 (d, *J* = 8.0 Hz, 1H), 8.03 (t, *J* = 7.7 Hz, 1H), 7.52–7.48 (m, 2H), 7.36–7.34 (m, 1H), 7.30–7.25 (m, 2H), 4.53 (q, *J* = 7.1 Hz, 2H), 2.80 (s, 3H), 1.56 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 166.0, 150.0, 149.9, 145.0, 138.6, 136.5, 126.7, 123.3, 122.7, 122.3, 122.1, 121.4, 110.2, 106.2, 59.6, 14.5, 13.1; IR (KBr) v 2924, 1691, 1588, 1543, 1468, 1436, 1397, 1268, 1178, 1115, 1078, 784, 747 cm⁻¹; HRMS (EI) calcd for C₁₇H₁₆N₂O₂ [M]⁺ 280.1212, found 280.1215.

Methyl 2-methyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (5c)



¹H NMR (500 MHz, CDCl₃) δ 8.75 (d, J = 5.0 Hz, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7.98 (td, J = 8.5, 2.0 Hz, 1H), 7.48–7.43 (m, 2H), 7.32–7.26 (m, 1H), 7.24–7.21 (m, 2H), 4.01 (s, 3H), 2.75 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.4, 150.1, 150.0, 145.1, 138.6, 136.6, 126.6, 123.3, 122.7, 122.3, 122.1, 121.4, 110.3, 106.1, 50.8, 13.1; IR (KBr) υ 3055, 2946, 1698, 1588, 1544, 1469, 1435, 1394, 1270, 1192, 1116, 1082, 784, 749 cm⁻¹; HRMS (EI) calcd for C₁₆H₁₄N₂O₂ [M]⁺ 266.1055, found 266.1057.

tert-Butyl 2-methyl-1-(pyridin-2-yl)-1H-indole-3-carboxylate (5d)



¹H NMR (500 MHz, CDCl₃) δ 8.78 (br s, 1H), 8.22 (d, J = 8.0 Hz, 1H), 8.00 (td, J = 8.5, 2.0 Hz, 1H), 7.50–7.45 (m, 2H), 7.32–7.26 (m, 1H), 7.24–7.21 (m, 2H), 2.75 (s, 3H), 1.74 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 165.4, 150.3, 150.0, 144.5, 138.5, 136.5, 126.8, 123.2, 122.6, 122.2, 122.1, 121.4, 110.2, 107.5, 80.0, 28.7, 13.2; IR (KBr) υ 2974, 2928, 1685, 1588, 1541, 1468, 1435, 1391, 1364, 1276, 1201, 1159, 1113, 1098, 1079, 1022, 993, 785, 740 cm⁻¹; HRMS (EI) calcd for C₁₉H₂₀N₂O₂ [M]⁺ 308.1525, found 308.1524.

Benzyl 2-methyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (5e)



¹H NMR (500 MHz, CDCl₃) δ 8.75 (d, *J* = 4.5 Hz, 1H), 8.22 (d, *J* = 8.0 Hz, 1H), 7.97 (td, *J* = 8.5, 2.0 Hz, 1H), 7.55 (d, *J* = 7.5 Hz, 2H), 7.47–7.43 (m, 4H), 7.38 (t, *J* = 7.0 Hz, 1H), 7.30–7.20 (m, 3H), 5.50 (s, 2H), 2.75 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 165.7, 150.1, 150.0, 145.4, 138.5, 136.8, 136.6, 128.5, 127.9, 127.8, 126.7, 123.3, 122.7, 122.4, 122.1, 121.5, 110.3, 105.9, 65.4, 13.2; IR (KBr) v 3056, 2980, 2931, 1693, 1587, 1541, 1469, 1437, 1400, 1267, 1177, 1115, 1075, 1025, 995, 783, 748, 698 cm⁻¹; HRMS (EI) calcd for C₂₂H₁₈N₂O₂ [M]⁺ 342.1368, found 342.1370.

Ethyl 2-propyl-1-(pyridin-2-yl)-1H-indole-3-carboxylate (5f)



¹H NMR (500 MHz, CDCl₃) δ 8.85 (d, *J* = 3.5 Hz, 1H), 8.34 (d, *J* = 8.0 Hz, 1H), 8.07 (td, *J* = 8.5, 2.0 Hz, 1H), 7.58–7.54 (m, 2H), 7.39 (t, *J* = 8.0 Hz, 1H), 7.30 (t, *J* = 8.0 Hz, 1H), 7.25 (d, *J* = 8.0 Hz, 1H), 4.58 (q, *J* = 7.0 Hz, 2H), 3.28 (t, *J* = 6.5 Hz, 2H), 1.74–1.69 (m, 2H), 1.61 (t, *J* = 7.0 Hz, 3H), 0.98 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 165.7, 150.4, 150.0, 149.6, 138.5, 136.8, 126.8, 123.4, 122.7, 122.4, 122.3, 121.6, 110.2, 105.7, 59.5, 27.9, 22.9, 14.5, 14.0; IR (KBr) v 3362, 2961, 2929, 1692, 1587, 1532, 1467, 1436, 1321, 1273, 1180, 1069, 993, 746, 696 cm⁻¹; HRMS (EI) calcd for C₁₉H₂₀N₂O₂ [M]⁺ 308.1525, found 308.1523.

Ethyl 5-methoxy-2-methyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (5h)



¹H NMR (500 MHz, CDCl₃) δ 8.69 (s, 1H), 7.92 (dt, J = 8.5, 1.5 Hz, 1H), 7.71 (d, J = 2.5 Hz, 1H), 7.41–7.37 (m, 2H), 7.10 (d, J = 9.0 Hz, 1H), 6.80 (dd, J = 9.0, 2.5 Hz, 1H), 4.42 (q, J = 7.0 Hz, 2H), 3.89 (s, 3H), 2.69 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.0, 156.0, 150.3, 149.9, 145.0, 138.5, 131.6, 127.7, 123.2, 121.9, 112.3, 111.1, 106.1, 103.6, 59.5, 55.7, 14.5, 13.3; IR (KBr) υ 2980, 2927, 1688, 1581, 1539, 1469, 1434, 1399, 1270, 1186, 1160, 1078, 1032, 851, 780, 747 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₈N₂O₃ [M]⁺ 310.1317, found 310.1312.





¹H NMR (500 MHz, CDCl₃) δ 8.70 (d, J = 3.5 Hz, 1H), 7.98 (s, 1H), 7.92 (dt, J = 8.5, 2.0 Hz, 1H), 7.41–7.37 (m, 2H), 7.09 (d, J = 8.0 Hz, 1H), 6.99 (d, J = 8.5 Hz, 1H), 4.43 (q, J = 7.0 Hz, 2H), 2.69 (s, 3H), 2.48 (s, 3H), 1.47 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.1, 150.3, 149.9, 144.8, 138.5, 135.0, 131.7, 127.0, 124.1, 123.1, 122.0, 121.2, 109.9, 105.9, 59.5, 21.6, 14.6, 13.2; IR (KBr) υ 2976, 2923, 1687, 1588, 1541, 1469, 1434, 1397, 1268, 1197, 1150, 1132, 1075, 1035, 993, 883, 782 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₈N₂O₂ [M]⁺ 294.1368, found 294.1363.

Ethyl 2-methyl-1-(pyridin-2-yl)-5-(trifluoromethoxy)-1*H*-indole-3-carboxlate (5j)



¹H NMR (500 MHz, CDCl₃) δ 8.72 (d, J = 4.5 Hz, 1H), 8.04 (br s, 1H), 7.96 (td, J = 8.6, 2.0 Hz, 1H), 7.48–7.44 (m, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.18 (d, J = 9.0 Hz, 1H), 7.03 (dd, J = 8.8 Hz, 1H), 4.43 (q, J = 7.0 Hz, 2H), 2.70 (s, 3H), 1.47 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 165.4, 150.1, 149.8, 146.6, 144.9, 138.8, 134.8, 127.3, 123.6, 122.0, 120.7 (q, $J_{C-F} = 254.4$ Hz), 116.4, 114.0, 111.1, 106.5, 59.8, 14.4, 13.2; IR (KBr) υ 3474, 2982, 2931, 1695, 1467, 1245, 1148, 1078, 781 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₅F₃N₂O₃ [M]⁺ 364.1035, found 364.1031.





¹H NMR (500 MHz, CDCl₃) δ 8.70 (d, *J* = 3.5 Hz, 1H), 8.15 (s, 1H), 7.95 (dt, *J* = 8.5, 1.5 Hz, 1H), 7.45–7.43 (m, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 7.11 (s, 1H), 4.43 (q, *J* = 7.0 Hz, 2H), 3.89 (s, 3H), 2.69 (s, 3H), 1.47 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 165.0, 150.1, 149.8, 146.1, 138.7, 128.1, 127.8, 123.5, 122.9, 122.0, 121.1, 111.4, 106.0, 59.8, 14.5, 13.2; IR (KBr) v 3062, 2978, 2926, 1692, 1587, 1541, 1435, 1396, 1183, 1085, 877, 780, 746 cm⁻¹; HRMS (EI) calcd for C₁₇H₁₅ClN₂O₂ [M]⁺ 314.0822, found 314.0821.

Ethyl 6-methoxy-2-methyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (5l)



¹H NMR (500 MHz, CDCl₃) δ 8.71 (d, J = 5.0 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.94 (td, J = 8.5, 2.0 Hz, 1H), 7.44–7.40 (m, 1H), 7.38 (d, J = 8.0 Hz, 1H), 6.90 (dd, J = 8.5, 2.0 Hz, 1H), 6.71 (d, J = 2.0 Hz, 1H), 4.42 (q, J = 7.0 Hz, 2H), 3.76 (s, 3H), 2.66 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.0, 156.7, 150.2, 150.0, 143.9, 138.6, 137.3, 123.3, 122.1, 122.0, 120.8, 111.1, 106.1, 94.7, 59.5, 55.6, 14.5, 13.1; IR (KBr) v 3053, 2978, 2927, 1691, 1586, 1548, 1468, 1435, 1266, 1186, 1159, 1078, 1027, 819, 780, 747 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₈N₂O₃ [M]⁺ 310.1317, found 310.1317.





¹H NMR (500 MHz, CDCl₃) δ 8.71 (d, J = 3.5 Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.94 (td, J = 8.5, 2.0 Hz, 1H), 7.43–7.38 (m, 2H), 7.08 (d, J = 8.0 Hz, 1H), 6.99 (s, 1H), 4.42 (q, J = 7.0 Hz, 2H), 2.68 (s, 3H), 2.40 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.1, 150.3, 149.9, 144.3, 138.5, 137.0, 132.6, 124.5, 123.9, 123.2, 122.1, 121.1, 110.2, 106.1, 59.5, 21.6, 14.5, 13.0; IR (KBr) ν 3053, 2979, 2923, 1691, 1542, 1468, 1436, 1387, 1267, 1192, 1129, 1078, 1031, 810, 781, 747 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₈N₂O₂ [M]⁺ 294.1368, found 294.1367.

Ethyl 6-fluoro-2-methyl-1-(pyridin-2-yl)-1H-indole-3-carboxylate (5n)



¹H NMR (500 MHz, CDCl₃) δ 8.72 (d, J = 3.5 Hz, 1H), 7.95 (td, J = 9.0, 2.0 Hz, 1H), 7.46–7.44 (m, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.10–7.06 (m, 1H), 6.95–6.89 (m, 2H), 4.40 (q, J = 7.0 Hz, 2H), 2.61 (s, 3H), 1.43 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 165.2, 155.7 (d, $J_{C-F} = 250.0$ Hz), 150.1 (d, $J_{C-F} = 8.6$ Hz), 144.2, 139.3 (d, $J_{C-F} = 10.0$ Hz), 138.7, 123.6, 123.3 (d, $J_{C-F} = 8.0$ Hz), 122.3, 114.7 (d, $J_{C-F} = 19.0$ Hz), 108.5 (d, $J_{C-F} = 21.8$ Hz), 106.4 (q, $J_{C-F} = 3.8$ Hz), 105.8 (d, $J_{C-F} = 3.0$ Hz), 60.1, 14.3, 13.0; IR (KBr) υ 3056, 2980, 2929, 1692, 1587, 1542, 1468, 1434, 1398, 1219, 1154, 1079, 766, 726 cm⁻¹; HRMS (EI) calcd for C₁₇H₁₅FN₂O₂ [M]⁺ 298.1118, found 298.1121.

Ethyl 6-chloro-2-methyl-1-(pyridin-2-yl)-1H-indole-3-carboxylate (50)



¹H NMR (500 MHz, CDCl₃) δ 8.72 (d, J = 4.5 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H), 7.96 (td, J = 8.5, 2.0 Hz, 1H), 7.47–7.43 (m, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.22–7.20 (m, 2H), 4.42 (q, J = 7.5 Hz, 2H), 2.68 (s, 3H), 1.46 (t, J = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 165.6, 150.1, 149.6, 145.5, 138.8, 136.9, 128.6, 125.3, 123.6, 122.8, 122.4, 122.0, 110.4, 106.3, 59.7, 14.5, 13.1; IR (KBr) υ 3055, 2978, 2930, 1693, 1587, 1545, 1470, 1437, 1396, 1262, 1196, 1125, 1063, 813, 786, 747 cm⁻¹; HRMS (EI) calcd for C₁₇H₁₅ClN₂O₂ [M]⁺ 314.0822, found 314.0821.

Ethyl 2,7-dimethyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (5p)



¹H NMR (500 MHz, CDCl₃) δ 8.68 (d, *J* = 3.5 Hz, 1H), 8.09 (d, *J* = 8.0 Hz, 1H), 7.88 (td, *J* = 8.5, 2.0 Hz, 1H), 7.48–7.46 (m, 1H), 7.32 (d, *J* = 8.0 Hz, 1H), 7.14 (t, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 7.0 Hz, 1H), 4.42 (q, *J* = 7.0 Hz, 2H), 2.50 (s, 3H), 1.78 (s, 3H), 1.46 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.0, 152.1, 149.4, 145.5, 138.1, 135.6, 127.2, 125.3, 124.3, 124.2, 122.0, 120.8, 119.4, 105.5, 59.5, 18.8, 14.5, 12.6; IR (KBr) υ 3048, 2978, 2927, 1692, 1587, 1551, 1469, 1438, 1399, 1245, 1201, 1098, 792, 744 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₈N₂O₂ [M]⁺ 294.1368, found 294.1363.

General procedure and characterization for C7-alkylation of indole 5b

To an oven-dried sealed tube charged with ethyl 2-methyl-1-(pyridin-2-yl)-*1H*-indole-3-carboxylate (**5b**) (56.1 mg, 0.2 mmol, 100 mol %), [RhCp*Cl₂]₂ (3.1 mg, 0.005 mmol, 2.5 mol %), and AgSbF₆ (6.8 mg, 0.02 mmol, 10 mol %) in EtOH (1 mL) was diisopropyl 2diazomalonate (**2c**) (64.2 mg, 0.24 mmol, 150 mol %). The reaction mixture was allowed to stir at room temperature for 24 h. The reaction mixture was diluted with EtOAc (3 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (*n*hexanes/EtOAc: 4:1) to afford **3a** (83.7 mg) in 90% yield.

Diisopropyl 2-(3-(ethoxycarbonyl)-2-methyl-1-(pyridin-2-yl)-1*H*-indol-7-yl)malonate (7a)



¹H NMR (500 MHz, CDCl₃) δ 8.69 (d, *J* = 5.0 Hz, 1H), 8.20 (d, *J* = 7.5 Hz, 1H), 7.91 (t, *J* = 8.0 Hz, 1H), 7.50–7.48 (m, 1H), 7.29 (d, *J* = 8.0 Hz, 1H), 7.26–7.21 (m, 2H), 4.92–4.87 (m, 2H), 4.42 (q, *J* = 7.0 Hz, 2H), 3.96 (s, 1H), 2.42 (s, 3H), 1.43 (t, *J* = 7.5 Hz, 3H), 1.14 (d, *J* = 6.5 Hz, 6H), 1.12 (t, *J* = 6.5 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 167.4, 165.8, 151.7, 150.4, 146.1, 138.9, 135.0, 128.0, 124.5, 124.3, 124.2, 122.1, 121.5, 116.4, 106.0, 69.2, 59.6, 52.7, 21.5, 21.4, 14.5, 12.6; IR (KBr) υ 3051, 2980, 2933, 1726, 1695, 1467, 1438, 1241, 1167, 1097, 993, 801, 747 cm⁻¹; HRMS (EI) calcd for C₂₆H₃₀N₂O₆ [M]⁺ 466.2104, found 466.2104.

General procedure and characterization for C7-cyanation of indole 5b

To an oven-dried sealed tube charged with ethyl 2-methyl-1-(pyridin-2-yl)-*1H*-indole-3-carboxylate (**5b**) (56.1 mg, 0.2 mmol, 100 mol %), [RhCp*Cl₂]₂ (6.2 mg, 0.01 mmol, 5 mol %), AgSbF₆ (13.7 mg, 0.04 mmol, 20 mol %), and NaOAc (4.9 mg, 0.06 mmol, 30 mol %) in DCE (1 mL) was added *N*-cyano-*N*-phenyl-*p*-methylbenzenesulfonamide (NCTS) (**6a**) (108.9 mg, 0.4 mmol, 200 mol %). The reaction mixture was allowed to stir at 110 °C for 24 h, and cooled to room temperature. The reaction mixture was diluted with EtOAc (3 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc = 4:1) to afford **7b** (28.1 mg) in 46% yield.

Ethyl 7-cyano-2-methyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (7b)



¹H NMR (500 MHz, CDCl₃) δ 8.76 (d, J = 5.5 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.01 (td, J = 9.0, 2.0 Hz, 1H), 7.60–7.57 (m, 1H), 7.49 (d, J = 7.5 Hz, 1H), 7.45 (d, J = 7.5 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 4.43 (q, J = 7.0 Hz, 2H), 2.59 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 165.1, 150.2, 148.9, 146.9, 138.8, 135.7, 128.9, 128.0, 126.8, 125.4, 124.3, 121.9, 116.0, 106.2, 94.8, 60.0, 14.5, 12.7; IR (KBr) v 3054, 2923, 2853, 1698, 1468, 1443, 1258, 1087, 799, 740 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₅N₃O₂ [M]⁺ 305.1164, found 305.1168.

General procedure and characterization for C7-amidation of indole 5b

To an oven-dried sealed tube charged with ethyl 2-methyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (**5b**) (56.1 mg, 0.2 mmol, 100 mol %), [RhCp*Cl₂]₂ (6.2 mg, 0.01 mmol, 5 mol %) and AgSbF₆ (13.7 mg, 0.04 mmol, 20 mol %) was added *n*-butyl isocyanate (**6b**) (67.5 μ L, 0.6 mmol, 300 mol %) and DCE (1 mL) under N₂ atmosphere. The reaction mixture was allowed to stir at 100 °C for 24 h and cooled to room temperature. The reaction mixture was diluted with EtOAc (3 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (n-hexanes/EtOAc = 2:1) to afford **7c** (46.2 mg) in 61% yield.

Ethyl 7-(butylcarbamoyl)-2-methyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (7c)



¹H NMR (500 MHz, CDCl₃) δ 8.57 (d, *J* = 4.5 Hz, 1H), 8.32–8.29 (m, 1H), 7.94 (td, *J* = 9.0, 2.0 Hz, 1H), 7.43–7.40 (m, 2H), 7.27–7.25 (m, 2H), 5.75 (t, *J* = 5.0 Hz, 1H), 4.43 (q, *J* = 7.0 Hz, 2H), 2.88 (q, *J* = 6.0 Hz, 2H), 2.61 (s, 3H), 1.48 (t, *J* = 7.0 Hz, 3H), 1.37–1.28 (m, 4H), 0.91 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 167.8, 165.7, 151.3, 149.0, 146.4, 138.7, 132.5, 128.3, 123.7, 123.6, 123.2, 122.4, 121.8, 121.7, 106.3, 59.8, 39.5, 31.2, 20.0, 14.5, 13.7, 13.0; IR (KBr) υ 3325, 2956, 2926, 1698, 1630, 1553, 1468, 1250, 1184, 1091, 744 cm⁻¹; HRMS (EI) calcd for C₂₂H₂₅N₃O₃ [M]⁺ 379.1896, found 379.1889.

General procedure and characterization for the transformation of 3a

To an oven-dried sealed tube charged with dimethyl 2-(2-(pyrimidin-2ylamino)phenyl)malonate (**3a**) (60.2 mg, 0.2 mmol, 100 mol %) in toluene (5 mL) was added DBU (121.7 mg, 0.8 mmol, 400 mol %). The reaction mixture was allowed to stir at 110 °C for 12 h. Upon completion, the solvent was removed under vacuum. The mixture was extracted with EtOAc (3 × 10 mL) and washed with brine. The organic layer was dried over Mg₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc = 1:1.5) to afford **8a** (23.9 mg) in 42% yield.

6-(Methoxycarbonyl)-6*H*-pyrimido[2,1-b]quinazoline-6-carboxylic acid (8a)



¹H NMR (500 MHz, CDCl₃) δ 8.89 (d, J = 4.5 Hz, 2H), 7.82 (d, J = 8.0 Hz, 1H), 7.43–7.38 (m, 2H), 7.30 (t, J = 4.9 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 4.42 (br s, 1H), 3.76 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 171.8, 170.0, 158.6, 155.6, 142.0, 130.6, 126.0, 124.7, 124.0, 119.1, 113.8, 77.5, 54.1; IR (KBr) v 3055, 2929, 1693, 1587, 1541, 1468, 1436, 1399, 1267, 1176, 1115, 1074, 995, 782 cm⁻¹; HRMS (EI) calcd for C₁₄H₁₁N₃O₄ [M]⁺ 285.0750, found 285.0750.

General procedure and characterization for deprotection of 5b

To a stirred solution of ethyl 2-methyl-1-(pyridin-2-yl)-1*H*-indole-3-carboxylate (**5b**) (56.1 mg, 0.2 mmol, 100 mol %) in DCM (5 mL) was added dropwise MeOTf (27 μ L, 0.24 mmol, 120 mol %) at 0 °C. The reaction mixture was allowed to stir for 24 h at room temperature. The solvent was removed under vacuum, and the residue was dissolved in EtOH (2.5 mL). An aqueous solution of 2 N NaOH (1.2 mL) was added to the reaction mixture, and the resulting mixture was stirred at 60 °C for 12 h and cooled to room temperature. The solvent was removed under reduced pressure and the mixture was diluted with EtOAc and washed with brine. The combined organic layer was dried over MgSO₄ and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc = 4:1) to afford **9a** (25.7 mg) in 63% yield.

Ethyl 2-methyl-1*H*-indole-3-carboxylate (9a)



¹H NMR (500 MHz, CDCl₃) δ 8.37 (br s, 1H), 8.10 (d, J = 7.0 Hz, 1H), 7.29 (d, J = 7.0 Hz, 1H), 7.22–7.18 (m, 2H), 4.40 (q, J = 7.0 Hz, 2H), 2.74 (s, 3H), 1.45 (t, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.0, 143.8, 134.5, 127.2, 122.3, 121.6, 121.3, 110.4, 104.7, 59.4, 14.6, 14.2; IR (KBr) υ 3303, 2922, 1714, 1659, 1550, 1456, 1367, 1271, 1196, 1120, 1091, 1010, 782, 732 cm⁻¹; HRMS (EI) calcd for C₁₂H₁₃NO₂ [M]⁺ 203.0946, 203.0945.

Experimental procedure and characterization for the synthesis of deuterio-4a



To an oven-dried flask charged with 2-bromopyridine (316 mg, 2 mmol, 100 mol %), aniline-d5 (385 mg, 2.4 mmol, 120 mol %), potassium *tert*-butoxide (449 mg, 4 mmol, 200 mol%), Pd(OAc)₂ (22.4 mg, 0.1 mmol, 5 mol%) and (\pm)-BINAP (62.2 mg, 0.1 mmol, 5 mol%) were taken and the reaction vessel was flushed with N₂. Dry toluene (6 mL) was added to it through the septum. The reaction mixture was stirred at 120 °C for 6 h and monitored by TLC. Upon completion, water was added and the mixture was extracted with EtOAc (3 × 10 mL). The combined organic phase was washed with brine and dried over Mg₂SO₄. The organic layer was evaporated in vacuum. The crude product was purified by flash column chromatography (*n*-hexanes/EtOAc = 6:1) to give **deuterio-4a** (297 mg) in 85% yield.

2',3',4',5',6'-Pentadeuterium-*N*-phenylpyridin-2-amine (deuterio-4a)⁵: ¹H NMR (500 MHz, CDCl₃) δ 8.20 (d, J = 4.5 Hz, 1H), 7.48 (t, J = 8.5 Hz, 1H), 6.98 (br s, 1H), 6.89 (d, J = 8.5 Hz, 1H), 6.74-6.71 (m, 1H).

Reference:

[5] M. Koley, N. Dastbaravardeh, M. Schnurch, and M. D. Mihovilovic, *ChemCatChem*, 2012, 4, 1345

Kinetic Isotope Effect (KIE) experiments



To an oven-dried sealed tube charged with *N*-phenylpyridin-2-amine (**4a**) (34.0 mg, 0.2 mmol, 100 mol %), [RhCp*Cl₂]₂ (3.1 mg, 0.005 mmol, 2.5 mol %) and AgOAc (5 mg, 0.03 mmol, 15 mol %) in MeOH (1 mL) was added ethyl 2-diazo-3-oxobutanoate (**2h**) (37.5 mg, 0.24 mmol, 120 mol %) and cyclohexanemethanol (22.8 mg, 0.2 mmol, 100 mol%) as an internal standard. In another reaction tube, **deuterio-4a** (35.0 mg, 0.2 mmol, 100 mol %) was used as a substrate under otherwise identical conditions. The two reactions were allowed to stir at 60 °C. An aliquot of each reaction mixture was taken at the time of 10 min, 20 min, 30 min, 40 min, and 50 min. The corresponding yield of each product was determined by GC (cyclohexanemethanol as an internal standard). A kinetic isotope effect value ($k_{\rm H}/k_{\rm D}$) of 1.02 was observed.

	Relative yield (%) based on cyclohexanemethanol				
	10 min	20 min	30 min	40 min	50 min
4 a	7.1615048	9.0632375	11.23016	12.835847	13.847292
deuterio-4a	8.837547	12.390344	13.843618	15.252313	15.814402



k _H	0.171
k _D	0.168
$k_{\rm H}/k_{\rm D}$	1.02



















PPM 160 140 120 100 80 60 40

20

file: ...\Desktop\NMR_Neeraj\NK653P.fid\fid block# 1 expt: "s2pul" transmitter freq.: 499.960210 MHz time domain size: 36372 points width: 9611.92 Hz = 19.2254 ppm = 0.264267 Hz/pt number of scans: 32

freq. of 0 ppm: 499.957003 MHz processed size: 65536 complex points LB: 1.000 GF: 0.0000

